Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers

V. Dobrotkova, P. Chlapek, M. Jezova, K. Adamkova, P. Mazanek, J. Sterba, R. Veselska,

. 2019 ; 14 (6) : e0218269. [pub] 20190612

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006266

Grant support
NV15-34621A MZ0 CEP Register

Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop resistance to retinoids during treatment. Our study focused on the comparative analysis of the expression of five genes and corresponding proteins (DDX39A, HMGA1, HMGA2, HOXC9 and PBX1) that have recently been discussed as possible predictive biomarkers of clinical response to retinoid differentiation therapy. Expression of these five candidate biomarkers was evaluated at both the mRNA and protein level in the same subset of 8 neuroblastoma cell lines after treatment with natural or synthetic retinoids. We found that the cell lines that were HMGA2-positive and/or HOXC9-negative have a reduced sensitivity to retinoids. Furthermore, the experiments revealed that the retinoid-sensitive cell lines showed a uniform pattern of change after treatment with both natural and sensitive retinoids: increased DDX39A and decreased PBX1 protein levels. Our results showed that in NBL cells, these putative protein biomarkers are associated with sensitivity or resistance to retinoids, and their endogenous or induced expression can distinguish between these two phenotypes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006266
003      
CZ-PrNML
005      
20201116145216.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0218269 $2 doi
035    __
$a (PubMed)31188873
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dobrotkova, Viera $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Kotlarska, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Pekarska, Czech Republic.
245    10
$a Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers / $c V. Dobrotkova, P. Chlapek, M. Jezova, K. Adamkova, P. Mazanek, J. Sterba, R. Veselska,
520    9_
$a Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop resistance to retinoids during treatment. Our study focused on the comparative analysis of the expression of five genes and corresponding proteins (DDX39A, HMGA1, HMGA2, HOXC9 and PBX1) that have recently been discussed as possible predictive biomarkers of clinical response to retinoid differentiation therapy. Expression of these five candidate biomarkers was evaluated at both the mRNA and protein level in the same subset of 8 neuroblastoma cell lines after treatment with natural or synthetic retinoids. We found that the cell lines that were HMGA2-positive and/or HOXC9-negative have a reduced sensitivity to retinoids. Furthermore, the experiments revealed that the retinoid-sensitive cell lines showed a uniform pattern of change after treatment with both natural and sensitive retinoids: increased DDX39A and decreased PBX1 protein levels. Our results showed that in NBL cells, these putative protein biomarkers are associated with sensitivity or resistance to retinoids, and their endogenous or induced expression can distinguish between these two phenotypes.
650    _2
$a mladiství $7 D000293
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a bexaroten $x farmakologie $7 D000077610
650    _2
$a biomarkery farmakologické $x metabolismus $7 D054316
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a DEAD-box RNA-helikasy $x genetika $x metabolismus $7 D053487
650    _2
$a chemorezistence $x účinky léků $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fenretinid $x farmakologie $7 D017313
650    _2
$a protein HMGA1A $x genetika $x metabolismus $7 D025741
650    _2
$a protein HMGA2 $x genetika $x metabolismus $7 D025743
650    _2
$a homeodoménové proteiny $x genetika $x metabolismus $7 D018398
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a isotretinoin $x farmakologie $7 D015474
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory nervového systému $x genetika $x metabolismus $x patologie $x chirurgie $7 D009423
650    _2
$a neuroblastom $x genetika $x metabolismus $x patologie $x chirurgie $7 D009447
650    _2
$a zalévání tkání do parafínu $7 D016612
650    _2
$a pre-B-buněčný leukemický transkripční faktor 1 $x genetika $x metabolismus $7 D000075062
650    _2
$a fixace tkání $7 D016707
650    _2
$a tretinoin $x analogy a deriváty $x farmakologie $7 D014212
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chlapek, Petr $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Kotlarska, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Pekarska, Czech Republic.
700    1_
$a Jezova, Marta $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska, Czech Republic.
700    1_
$a Adamkova, Katerina $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Kotlarska, Czech Republic.
700    1_
$a Mazanek, Pavel $u Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni, Czech Republic.
700    1_
$a Sterba, Jaroslav $u International Clinical Research Center, St. Anne's University Hospital, Pekarska, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni, Czech Republic.
700    1_
$a Veselska, Renata $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Kotlarska, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Pekarska, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 14, č. 6 (2019), s. e0218269
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31188873 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20201116145214 $b ABA008
999    __
$a ok $b bmc $g 1525124 $s 1096322
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 6 $d e0218269 $e 20190612 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV15-34621A $p MZ0
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options